Technical Analysis for CLRB - Cellectar Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -2.74% | |
| Bearish Engulfing | Bearish | -3.90% | |
| Earnings Movers | Other | -6.43% | |
| Wide Bands | Range Expansion | -6.43% | |
| Up 3 Days in a Row | Strength | -6.43% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.19% | |
| Crossed Above 20 DMA | Bullish | -4.19% | |
| MACD Bullish Signal Line Cross | Bullish | -4.19% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 10 hours ago |
| 60 Minute Opening Range Breakdown | about 11 hours ago |
| Fell Below 10 DMA | about 11 hours ago |
| 60 Minute Opening Range Breakout | about 13 hours ago |
| 10 DMA Support | about 13 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/14/2024
Cellectar Biosciences, Inc. Description
Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Imaging Oncology Stem Cell Chemotherapy Radiation Antineoplastic Drugs Occupational Safety And Health Blastoma Glioblastoma Radiation Therapy Targeted Therapy Advanced Solid Tumors Tomography Imaging Agent Positron Emission Tomography Cancer Stem Cell Cancer Stem Cells
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.45 |
| 52 Week Low | 1.36 |
| Average Volume | 994,882 |
| 200-Day Moving Average | 2.83 |
| 50-Day Moving Average | 3.58 |
| 20-Day Moving Average | 3.22 |
| 10-Day Moving Average | 3.20 |
| Average True Range | 0.20 |
| RSI (14) | 44.44 |
| ADX | 17.74 |
| +DI | 19.27 |
| -DI | 21.59 |
| Chandelier Exit (Long, 3 ATRs) | 3.23 |
| Chandelier Exit (Short, 3 ATRs) | 3.54 |
| Upper Bollinger Bands | 3.58 |
| Lower Bollinger Band | 2.87 |
| Percent B (%b) | 0.47 |
| BandWidth | 22.06 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.12 |
| MACD Histogram | 0.034 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.43 | ||||
| Resistance 3 (R3) | 3.44 | 3.37 | 3.39 | ||
| Resistance 2 (R2) | 3.37 | 3.31 | 3.37 | 3.38 | |
| Resistance 1 (R1) | 3.29 | 3.27 | 3.25 | 3.28 | 3.37 |
| Pivot Point | 3.22 | 3.22 | 3.20 | 3.21 | 3.22 |
| Support 1 (S1) | 3.13 | 3.16 | 3.10 | 3.12 | 3.03 |
| Support 2 (S2) | 3.06 | 3.12 | 3.06 | 3.02 | |
| Support 3 (S3) | 2.98 | 3.06 | 3.01 | ||
| Support 4 (S4) | 2.97 |
